Actively Recruiting
Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study
Led by Xinhua Zhang, MD · Updated on 2025-02-26
100
Participants Needed
8
Research Sites
169 weeks
Total Duration
On this page
Sponsors
X
Xinhua Zhang, MD
Lead Sponsor
G
Guangdong Provincial People's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, multicenter, observational real-world study to explore the second-line Pharmacotherapy patterns and clinical outcomes in GIST patients who progressed on or were intolerant to first-line anticancer treatment.
CONDITIONS
Official Title
Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who are aged 2018 years.
- Patients who have histologically confirmed metastatic or unresectable GIST.
- Patients who received imatinib at a fixed dose or 1 other TKI as prior treatment regimens.
- Patients who experienced intolerance to prior therapies must have objective disease progression before enrollment.
- Patients must have at least a measurable lesion according to mRECIST Version 1.1.
- Patients receiving second-line treatments according to current GIST national guidelines, including sunitinib, imatinib dose escalation, ripretinib, dasatinib, and other drugs.
- Patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2 at screening.
You will not qualify if you...
- Patients who previously received two or more TKIs as prior treatment regimens.
- Patients with a life expectancy of fewer than three months.
- Patients who are pregnant or breastfeeding.
- Patients with poor adherence or inability to complete follow-up.
- Patients deemed inappropriate for enrollment by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Actively Recruiting
2
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510014
Actively Recruiting
3
Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Actively Recruiting
4
The first affiliated hospital,Sun yat-sen university
Guangzhou, Guangdong, China
Actively Recruiting
5
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Actively Recruiting
6
Hainan Cancer Hospital
Haikou, Hannan, China
Actively Recruiting
7
Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Actively Recruiting
8
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Actively Recruiting
Research Team
Z
zhang xinhua, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here